Navigation Links
InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
Date:9/17/2007

UK's Largest Pharmacy Distributor Introduces RESPeRATE Hypertension

Treatment Device Into Country's Retail Market

NEW YORK and LONDON, Sept. 17 /PRNewswire/ -- InterCure, Ltd. (TASE: INCR), today announced that its RESPeRATE(R) hypertension treatment device, clinically-proven in 10 peer-reviewed studies to significantly lower blood pressure, will launch into retail distribution in the United Kingdom through Mashco, Ltd., the country's largest distributor of healthcare diagnostics to the independent pharmacy market. The partnership marks a milestone for RESPeRATE, which has previously been sold directly to consumers through its website, http://www.resperate.com and through online resellers such as Amazon.com.

According to the terms of the agreement, Mashco will initially introduce RESPeRATE into 100 of its key retail partner locations beginning this month, with an emphasis on prominent stores which offer diagnostic blood pressure testing. Mashco will provide pharmacist education, patient information and an assortment of merchandising programs to introduce RESPeRATE as a valuable addition to patients' hypertension management regimens. In-store marketing will highlight the importance of combining diagnostic and therapeutic solutions to best manage hypertension under the guidance of a physician and pharmacist. Full rollout of RESPeRATE into the independent pharmacy market in the UK will occur immediately following the 100-store launch. Mashco currently serves 3,000 pharmacies in the United Kingdom.

"RESPeRATE's tremendous growth has been fueled by the massive numbers of frustrated hypertension sufferers who seek our safe, efficacious, non-drug treatment option," said Erez Gavish, president and CEO of InterCure. "Yet, two-thirds of our prospective customers tell us that they would prefer to buy RESPeRATE through their local pharmacy. InterCure's move into the UK independent pharmacy channel will allow consumers to buy from the professional they trust the most -- their pharmacist -- while establishing a strong retail footprint for InterCure and RESPeRATE. This marks the first step in a broad strategy to accelerate pharmacy distribution worldwide."

Almost one billion people worldwide have high blood pressure, including 38 percent of people in the UK. Traditional treatment methods of diet, exercise and medication are often unable to help patients reach their lower blood pressure goals. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.

"RESPeRATE complements well our existing pharmacy product offerings for hypertensives within the UK. We hope to add real value to the independent pharmacist and the patients they serve by providing a comprehensive approach for hypertension management," said Jay Mashru, director, Mashco.

About RESPeRATE

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure, Ltd.

InterCure, a medical device company, publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 75,000 units sold. With multiple published clinical studies, regulatory clearance in 13 key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)

About Mashco, Ltd.

Mashco, a specialist chemist distributor of personal diagnostics, small electrical appliances and photographic products, is the largest pharmacy distributor in the UK. Mashco has more than 25 years of experience in the chemist and supply trade, offering a comprehensive range of personal care products, including more than 400 brands of perfumes and skincare products. For more information, please visit http://www.mashco.com.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Jane Hauser Brian Packard

Schwartz Communications InterCure, Inc.

+1-781-684-0770 +1-646-652-5800 x.7134

intercure@schwartz-pr.com bpackard@intercure.com


'/>"/>
SOURCE InterCure, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):